Design and in Vitro Evaluation of a New Nano-Microparticulate System for Enhanced Aqueous-Phase Solubility of Curcumin by Guzman-Villanueva, Diana et al.
Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 724763, 9 pages
http://dx.doi.org/10.1155/2013/724763
Research Article
Design and In Vitro Evaluation of a New Nano-Microparticulate
System for Enhanced Aqueous-Phase Solubility of Curcumin
Diana Guzman-Villanueva,1,2 Ibrahim M. El-Sherbiny,3,4
Dea Herrera-Ruiz,2 and Hugh D. C. Smyth1
1 Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, TX 78712, USA
2 Facultad de Farmacia, Universidad Auto´noma del Estado de Morelos, 62209 Cuernavaca, MOR, Mexico
3 Polymer Laboratory, Faculty of Science, Mansoura University, Mansoura 35516, Egypt
4Center for Materials Science, Zewail University, Zewail City of Science and Technology, 6th of October City, Giza 12588, Egypt
Correspondence should be addressed to Hugh D. C. Smyth; hsmyth@mail.utexas.edu
Received 11 April 2013; Revised 23 June 2013; Accepted 25 June 2013
Academic Editor: Mohamad A. Hussein
Copyright © 2013 Diana Guzman-Villanueva et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Curcumin, a yellow polyphenol derived from the turmeric Curcuma longa, has been associated with a diverse therapeutic potential
including anti-inflammatory, antioxidant, antiviral, and anticancer properties. However, the poor aqueous solubility and low
bioavailability of curcumin have limited its potential when administrated orally. In this study, curcumin was encapsulated in a
series of novel nano-microparticulate systems developed to improve its aqueous solubility and stability.The nano-microparticulate
systems are based entirely on biocompatible, biodegradable, and edible polymers including chitosan, alginate, and carrageenan.
The particles were synthesized via ionotropic gelation. Encapsulating the curcumin into the hydrogel nanoparticles yielded a
homogenous curcumin dispersion in aqueous solution compared to the free form of curcumin. Also, the in vitro release profile
showed up to 95% release of curcumin from the developed nano-microparticulate systems after 9 hours in PBS at pH 7.4 when
freeze-dried particles were used.
1. Introduction
Curcumin, a natural yellow polyphenol present in the root
of Curcuma longa, has been commonly used in the food
industry as a food spice and coloring agent [1, 2]. It has been
demonstrated that curcumin possesses multiple pharmaco-
logical activities including anti-inflammatory, antioxidant,
antihyperlipidemic, antiulcer, immunomodulatory, neuro-
protective, antineoplastic, and chemoprotective properties
[3–8]. These therapeutic characteristics are mediated via
downregulation of transcription factors such as nuclear factor
(NF-𝜅B), beta-catenin, hypoxia inducible factor (HIF)-1𝛼,
and cyclo-oxygenase-2 and the upregulation of PPAR-𝛾,
superoxide dismutase, and caspases [9–13]. Curcumin safety,
tolerability, and low toxicity have been well established in
human trials [14–16].
In spite of the diversity of bioactivities of curcumin and
its potential to prevent and treat diseases, its limited aqueous
solubility and instability in the gastrointestinal tract yield
poor oral absorption, low bioavailability [1, 5, 9, 17], and poor
therapeutic performance [18–20]. Low serum levels as well as
limited tissue distribution and rapid metabolism have been
reported when curcumin is administrated [18].
Formulations based on liposomes, micelles, microemul-
sions, nanocrystal and amorphous solid dispersions, and gas-
troretentive floating systems have been developed to improve
the curcumin oral bioavailability [17–23]. However, a consid-
erable interest has recently been paid to the development of
polymeric nanoparticles-based drug delivery systems [5, 23–
26] due to these systems ability to overcome several problems
related to the delivery of hydrophobic drugs dispersed in
aqueous solutions.
Polymers derived from natural sources have been used
extensively in the pharmaceutical and food industry. Among
these polymers, polysaccharides have been widely utilized
because of their biocompatibility, biodegradability, and low
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toxicity. Chitosan, a natural polymer obtained from the dea-
cetylation of chitin, has been a useful polymer for var-
ious biomedical applications, sustained drug release and
for enhancement of bioavailability of poor water-soluble
drugs. Its wide range of applications makes this polymer an
attractive candidate for oral drug and supplement delivery
applications [27–31].
Alginate, a linear polysaccharide consisting of 𝛼-L-
guluronic acid (G) and 𝛽-D-mannuronic acid (M) residues
joined together in blocks, is commonly used due to its
mucoadhesive properties and its ability to form three-dimen-
sional hydrogel networks. The ability of alginate to form
hydrogels is attributed to the capacity of its guluronic acid
residues to bind with multivalent cations such as Ca2+
through ionic interactions [32, 33].The alginate-based hydro-
gel networks have been found very efficient in entrapment
and controlled delivery of a variety of ingredients including
drugs, proteins, bacteria, enzymes, and cells [34–36].
Carrageenan is another important hydrophilic polysac-
charide composed of D-galactose and 3,6-anhydro-D-galac-
tose units. According to the number and position of sulfate
groups, carrageenans are classified as kappa (𝜅), iota (𝛾),
alpha (𝛼), beta (𝛽), lambda (𝜆), and theta (𝜃) [33]. Car-
rageenan is commonly used in food products as a thickening
and stabilizing agent, and it has been recently introduced to
pharmaceutical formulations for controlled release purposes
due to its gelling ability [37–39]. Under appropriate condi-
tions, the gelation of 𝜅-carrageenan occurs in the presence of
potassium ions forming strong gels that can be used as drug
carriers [28].
The purpose of this study was to develop and evaluate
curcumin-loaded nano-microparticulate systems to improve
the solubility and stability of curcumin in gastrointestinal
(GI) conditions.These nano-microparticles carriers are based
on naturally occurring polymers including chitosan, car-
rageenan, and alginate which have desirable characteristics
such as biocompatibility, biodegradability, and nontoxicity.
Encapsulation of the curcumin-loaded chitosan nanopar-
ticles into alginate-carrageenan matrices would confer pro-
tection and stability to curcumin during its transit along the
GI tract, thus increasing the amount of curcumin available
to exert its pharmacological effect. Moreover, the presence of
alginate in the developed hydrogel matrices allows sustained
release of curcumin as the particles pass down the GI tract
[40, 41]. In addition, this study reports the effect of polymer
composition and drying method on the surface morphology
and size of the developed nano-microcarriers, as well as on
the release behavior of curcumin from the developed nano-
microparticle systems.
2. Experimental
2.1. Materials. Curcumin from Curcuma longa (turmeric),
Chitosan (medium MW, % N-deacetylation about 76.4%,
as determined by elemental analysis), sodium alginate (low
viscosity, 250 cps for 2% w/v solution at 25∘C), carrageenan
of commercial grade type I, sodium triphosphate pentaba-
sic (TPP) of practical grade 90–95%, and potassium chlo-
ride were obtained from Sigma Aldrich (St. Louis, MO).
Polyvinyl alcohol (PVA), 99-100% hydrolyzed, MW 86000,
was obtained from Acros organics (New Jersey, USA); anhy-
drous calcium chloride was purchased from EMDChemicals
Inc. (Darmstadt, Germany). Phosphate-buffered saline (PBS,
pH 2.1 and 7.4) and all other reagents were of analytical grade
and used as received.
2.2. Methods
2.2.1. Preparation of Curcumin-Loaded Chitosan Nanoparti-
cles. The curcumin-loaded chitosan nanoparticles were pre-
pared using the ionotropic gelation technique. Briefly, an
aqueous chitosan solution (0.05% w/v) was prepared using
5mL of 0.06M acetic acid and made up to a 500mL with
distilledwater.Then, 50𝜇L of 2% (w/v) aqueous PVA solution
and 80mL of 0.1% TPP solution were mixed and added to
200mL of chitosan solution. The final mixture was sonicated
using an ultrasonic processor (Misonixsonicator 4000, NY,
USA) for 4min with dropwise addition of the alcoholic
curcumin solution (0.5 g of curcumin dissolved in 15mL
of ethanol) to obtain a final concentration of 1.7mg/mL
of curcumin. The curcumin-loaded chitosan nanoparticle
dispersion was then kept in a fume hood under stirring to
allow ethanol evaporation and then used in the next step.
2.2.2. Preparation of Alginate-Carrageenan Hydrogel Micro-
particles. Different hydrogel matrices based on sodium algi-
nate and carrageenan containing curcumin-loaded chitosan
nanoparticles were developed via ionotropic gelation using
a crosslinking mixture of calcium and potassium chlo-
ride solutions (Table 1). Briefly, 20mL of curcumin-loaded
chitosan nanoparticle suspension prepared in Section 2.2.1
was added dropwise while stirring to alginate-carrageenan
solutions of different compositions maintaining the final
polymer concentration constant (2% w/v) in all formulations
(Table 1). Each polymer mixture was extruded while stirring
in 80mL (1 : 1, 3% w/v) of a calcium chloride and potassium
chloride solution using a syringe with a 21-gauge needle. The
formedmicroparticleswere kept for 15min in the crosslinkers
solution with slow stirring to complete the crosslinking.
Finally, the crosslinked microparticles were collected and
washed with distilled water (20mL) to remove the unreacted
polymers. The obtained microparticles were fractioned and
either freeze-dried or air-dried at room temperature and then
stored for further analysis.
2.2.3. Particle Size Measurements. The size of the curcumin-
loaded chitosan nanoparticles was determined by SEM (scan-
ning electron microscopy, Zeiss Supra 40VP) with the aid
of the ImageJ software 1.44o version (NIH). The diameters
of the hydrogel microparticles were measured using a digital
micrometer (General Ultra-Tech).
2.2.4. Particle Morphology Characterization. The morphol-
ogy of the developed hydrogel microparticles was investi-
gated by scanning electron microscopy (SEM, Zeiss Supra
40VP).Thedried particles weremounted on aluminum stubs
and coated with a 50/50 mixture of Au/Pd and then scanned
at a 10 kV.
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Table 1: Composition of the developed alginate-carrageenan hydrogel microparticles encapsulating curcumin-loaded chitosan nanoparticles
and its influence on the particle size.
Formulation
code Drying
Curcumin-loaded
chitosan particles (mL) Alginate (w%) Carrageenan (w%) CaCl2 (%) KCl (%)
Average geometric
size (𝜇m) ± SD
F1 FD 20 100 0 3 3 1034 ± 0.1
AD 20 100 0 3 3 831 ± 0.1
F2 FD 20 70 30 3 3 1210 ± 0.2
AD 20 70 30 3 3 1026 ± 0.1
F3 FD 20 50 50 3 3 2064 ± 0.2
AD 20 50 50 3 3 1171 ± 0.3
FD: freeze-dried, AD: air-dried.
2.2.5. Swelling Behavior of the Hydrogel Microparticles. The
swelling behavior of the freeze-dried and air-dried hydro-
gel nano-microparticles was studied by incubating certain
amount of particles (10–15mg) in an Eppendorf tube con-
taining 1.5mL of PBS (pH 2.1 or 7.4) with shaking at 100 rpm
at 37∘C. At predetermined intervals (1 and 2 h incubation at
pH 2.1 and 3, 4, 5, 6, 7, 8 up to 24 h incubation at pH 7.4),
swollen samples were removed from the PBS solution and
weighted after blotting their surface to calculate their swelling
percentages using the following relationship [42].
𝑆 (%) =
𝑊
𝑡
−𝑊
0
𝑊
0
× 100, (1)
where 𝑊
0
is the initial weight and 𝑊
𝑡
is the weight of the
swollen particles at time 𝑡. The swelling data represents the
average ± SD from three independent swelling experiments.
2.2.6. Release Study. The cumulative release of curcumin
from the developed hydrogel nano-microparticles was car-
ried out through incubating preweighed samples (10–15mg)
while shaking at 100 rpm in 1mL of buffer solutions at pH
2.1 (1 and 2 h incubation) or at pH 7.4 (3, 4, 5, 6, 7, 8 up to
24 h incubation) at 37∘C. After incubation, 100 𝜇L aliquots
were removed from the buffer solution to be analyzed by UV-
Vis spectrophotometry (Infinite M 200 fluorophotometer,
TECAN, USA) at 𝜆max of 430 nm. The withdrawn sample
was replaced with equal volume of fresh buffer solution to
keep the volume of release fluid constant. The collected data
represents the mean ± SD from three independent release
experiments.
2.2.7. Statistical Analysis. All the data was obtained from
three independent experiments analyzed and expressed as
mean ± SD.
3. Results and Discussion
3.1. Preparation of Curcumin-Loaded Chitosan Nanoparti-
cles. Chitosan-based nanoparticles were prepared by the
ionotropic gelation method and investigated as potential
carriers that could enhance the solubility and bioavailability
of curcumin (Scheme 1). As can be noted from Figure 1(a)-
(i), the free curcumin (100mg/mL) formed a large flocculate
on the surface due to its very limited solubility in water
(0.6 𝜇g/mL) [43]. In contrast, the curcumin encapsulated into
chitosan nanoparticles was homogenously dispersed in water
at a higher concentration (180mg/mL) (see Figure 1(a)-(ii)).
Furthermore, the curcumin nanosuspension displayed the
natural intense yellow color from curcumin, which could
be an indicative of the curcumin incorporation into the
nanoparticle dispersion. In contrast, free curcumin was not
incorporated into the aqueous environment, and most of
it was precipitated. Thus, the encapsulation of curcumin
into chitosan nanoparticles may be beneficial in improving
the curcumin concentration and enhancing its dispersity
in aqueous solution, which consequently may improve cur-
cumin dissolution and the resulting bioavailability when
administrated orally.
3.2. Preparation of Alginate-Carrageenan Hydrogel Micropar-
ticles. Alginate-carrageenan hydrogel microparticles were
obtained via ionotropic gelation of a mutual aqueousmixture
of alginate and carrageenan through interactions with their
counter ions (Ca2+ and K+ ions, resp.) as shown in Scheme 1.
During the preparation of the hydrogel matrices, it was
microscopically observed that stable microparticles were
instantaneously crosslinked and formed when only alginate
was present (100%, F1 formulation). Conversely, for for-
mulations containing carrageenan (30%–50%, F2 and F3),
the gelation process took place more slowly depending on
the carrageenan content in each formulation, leading to
the formation of less spherical matrices compared with the
microparticles based on alginate alone (Figures 1(b) and 1(c)).
This may be attributed to the different ionotropic gelation
mechanisms proposed for alginate and carrageenan [33].
Alginate is commonly crosslinked with Ca2+ by ionic inter-
chain bonding, while potassium interacts with carrageenan
creating only an intermolecular glue-like effect through
the electrostatic attraction with the sulfate ester groups of
carrageenan. This glue-like effect leads to the formation of
matrices with weak entanglement, which means that higher
potassium levels (≥0.3M) could be required to produce
more stable carrageenan gels. However, these high potassium
levels may be undesirable for medical applications as they
may cause arrhythmia and severe muscle weakness due
to hyperkalemia, such as previously reported by Poncelet
et al. [32], who also confirmed that in the presence of low
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Scheme 1: Schematic illustration of the developed curcumin-loaded nano-microparticles.
concentrations of crosslinking solution (Ca2+ for alginate and
K+ for carrageenan), alginate alone forms relatively more
stable hydrogels than carrageenan alone [32].
3.3. Particle Size Analysis. The average particle size of the
curcumin-loaded chitosan nanoparticles was found to be
480 ± 70 nm as determined by SEM and quantified by using
the ImageJ software. The size of all the developed alginate-
carrageenan hydrogel microparticles formulations was mea-
sured using a digital micrometer (General Ultra-Tech). As
seen in Table 1, the freeze-dried microparticles showed rel-
atively larger geometric sizes when compared with the air-
dried microparticles. It can also be noted that regardless of
the drying method, the formulations containing carrageenan
resulted in larger microparticles, especially the formulations
containing higher contents of carrageenan (FD3 and AD3),
as compared with the formulations containing alginate only
(FD1 and AD1). This may be attributed to the strong ability
of the sodium alginate to form crosslinked networks upon
interaction with the Ca2+ as compared to the crosslinking
ability of the carrageenan. Consequently, increasing the
carrageenan content in the developed microparticles led to
a less compact structure and larger size.
3.4. Morphology of the Hydrogel Microparticles. The SEM
micrographs of microparticles containing different alginate-
carrageenan ratios are shown in Figure 2. According to
Figures 2(a) and 2(d), the microparticles containing algi-
nate were smoother and more spherical compared to the
microparticles including alginate and carrageenan.This effect
can be attributed to the higher crosslinking ability of alginate
relative to carrageenan.This crosslinking takes place instanta-
neously upon dropping sodium alginate into the crosslinking
solution (Ca2+) leading to geometrically stable particles. In
the case of formulations containing carrageenan (Figures
2(b), 2(c), 2(e), and 2(f)), the microparticles were less spheri-
cal, andwith rough and folded surfaces.Moreover, large pores
and surface cavities were observed when increasing the ratio
of carrageenan in freeze-dried microparticles (Figures 2(b)
and 2(c)), while air-dried microparticles were more compact
(Figures 2(e) and 2(f)). This behavior could be attributed to
the low concentration of K+ in the hardening solution, and
also to the reduced crosslinking efficiency of carrageenan
as compared to alginate, which led to the production of
nonspherical and less physically stable microparticles.
3.5. Swelling Study of Alginate-Carrageenan Microparticles.
The swelling behavior of both freeze-dried and air-dried
alginate-carrageenan hydrogel microparticles was studied by
immersing the microparticles in simulated gastric (pH 2.1, 1
and 2 h incubation) and simulated intestinal fluids (pH 7.4: 3
up to 24 h incubation).
Figures 3 and 4 compare the swelling behavior of the
freeze-dried samples with the air-dried samples under similar
conditions, respectively. For instance, the highest swelling
values reached for the freeze-dried samples: FD1, FD2, and
FD3 formulations were 1008 ± 9.3, 781 ± 11, and 544 ±
30% over their original values, respectively, whereas, the
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Figure 1: Photographs showing (a) (i) curcumin suspended in distilled water and (ii) aqueous suspension of curcumin-loaded chitosan
nanoparticles, and microscopic images showing the effect of composition on the general shape of the developed curcumin-loaded hydrogel
microparticles; (b) microparticles based on alginate alone and (c) microparticles composed of (50 : 50) alginate and carrageenan.
corresponding values for the air-dried samples: AD1, AD2,
and AD3 were 717.9 ± 10.53%, 512.3 ± 13.38%, and 192.60 ±
4.95, respectively. The swelling values of the freeze-dried
samples areattributed to the presence of pores or cavities,
which facilitated the internalization of swelling fluid into the
matrices. On the other hand, the compact structure of the
air-dried formulations hindered the diffusion of the swelling
fluid into the hydrogel particles and consequently led the
attainment of relatively lower swelling values at equilibrium.
As can be noted from Figures 3 and 4, both freeze-
dried and air-dried microparticles showed different swelling
behaviors in the simulated gastric fluid (SGF, pH 2.1) and in
the simulated intestinal fluid (SIF, pH 7.4). At pH 2.1 (first 2
hours), all hydrogel microparticles showed a lower swelling
extent as a consequence of the formation of hydrogen bonds
between the polymer carboxylic and OH groups which limits
their swelling, as previously reported by El-Sherbiny [41]. In
contrast, at pH 7.4, the same microparticles attained higher
swelling values. This behavior is attributed to the ionization
of the free alginate’s carboxylic groups into carboxylates
(COO−) in the intestinal fluid (pH 7.4), which consequently
generates repulsive forces between them and leads to higher
swelling values [41].The higher swelling in the intestinal fluid
enhances with increasing the alginate content in both freeze-
and air-dried hydrogelmicroparticles as seen in Figures 3 and
4. This is clearly observed in the formulations FD1 and AD1,
which are composed of 100% alginate.
From Figures 3 and 4, it can also be noted that at
both SGF (pH 2.1) and SIF (pH 7.4), the freeze-dried nano-
microparticles attained relatively higher swelling values at
equilibrium as compared to the air-dried particles. This
may be due to the relatively high porosity of the freeze-
dried particles as compared to the compact structure of the
corresponding air-dried particles [42]. This porosity in case
of the freeze-dried particles is attributed in particular to the
relatively high speed of solvent sublimation in presence of
the freeze dryer high vacuum, while in the case of air-dried
samples the solvent evaporation occurs very slowly leading
to a more compact structure of the hydrogel particles [42].
The preserved porosity of the freeze-dried hydrogel matrices
facilitates the entrance of swelling fluid into the hydrogel and
consequently causes higher equilibrium swelling values.
3.6. Curcumin Release Study. The in vitro cumulative
release profiles of curcumin from the developed alginate-
carrageenan microparticles were investigated using both
simulated gastric (pH 2.1) and intestinal solutions (pH 7.4) at
37∘C until 24 h were completed. As shown in Figures 5 and 6,
the curcumin release was higher at SIF (pH 7.4) than in SGF
(pH 2.1) for both freeze-dried and air-dried microparticles
6 BioMed Research International
100𝜇m
(a)
100𝜇m
(b)
100𝜇m
(c)
100𝜇m
(d)
100𝜇m
(e) (f)
Figure 2: Scanning electron micrographs of alginate-carrageenan freeze-dried hydrogel microparticles (a) FD1, (b) FD2, (c) FD3, and the
corresponding air-dried hydrogel microparticles (d) AD1, (e) AD2, and (f) AD3.
following the same behavior as their swelling described in
Section 3.5.
In acidic conditions (pH 2.1), the curcumin released from
either freeze-dried or air-dried microparticles was around
5 to 15% in all cases (see Figures 5 and 6). This suggests
that most of the curcumin in the developed microparticles
would be available to be absorbed within the intestinal tract
and protected from the harsh gastric fluid. No difference
was found in the curcumin release from all microparticles
during the first two hours in the gastric fluid, except for FD3
formulation (Figure 5). However, when the microparticles
were transferred to the SIF (pH 7.4), a slight and gradual
increase in the curcumin release was observed in all formu-
lations. This higher curcumin release could be related to the
increase in swelling as alginate’s carboxylic groups are ionized
as described earlier.
In the microparticles formulation based on alginate
alone, the percentage of curcumin released was found to
be around 38% and 39% for FD1 and AD1, respectively,
which is consistent with their expected high crosslinking.
Formulations FD2 and AD2 showed similar behavior. On the
other hand, the formulations FD3 and AD3 containing same
proportion (50 : 50) of alginate and carrageenan showed the
highest curcumin release percentages (96% and 48%, resp.),
since the matrices were built on weak entanglements driven
by the presences of carrageenan. In the particular case of
the FD3 sample, a very noticeable and high percentage of
curcumin was released. This high release can be attributed
to the presence of holes on the surface of FD3 sample
(Figure 2(c)), which ease the diffusion of the release medium
into the microparticles, compared to AD1, AD2, and AD3
(Figure 2), which formed more compact microparticles due
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Figure 3: Swelling profiles of freeze-dried alginate-carrageenan
microparticles of different compositions in simulated gastrointesti-
nal fluids (SGF: pH 2.1 and SIF: 7.4) at 37∘C.
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Figure 4: Swelling profiles of air-dried alginate-carrageenan micro-
particles of different compositions in simulated gastrointestinal
fluids (SGF: pH 2.1 and SIF: 7.4) at 37∘C.
to the air-drying method. FD1 (100% alginate) and FD2
(70% alginate) formulations showed similar release patterns
due to the higher content of alginate, which formed stable
microparticles compared to FD3 (50% alginate). Also, it was
noted that the FD3 microparticles were completely eroded
after 7 h in simulated gastrointestinal fluid, while the other
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Figure 5: pH dependent release patterns of curcumin from freeze-
dried alginate-carrageenan microparticles with different composi-
tion in simulated gastrointestinal fluids (SGF: pH 2.1 and SIF: 7.4) at
37∘C.
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Figure 6: pHdependent release patterns of curcumin fromair-dried
alginate-carrageenan microparticles with different composition in
simulated gastrointestinal fluids (SGF: pH 2.1 and SIF: 7.4) at 37∘C.
formulations were progressively degraded over time. This
reveals that the amount of carrageenan played an important
role in controlling drug release. Based on these findings we
are assuming that the release profile in FD3 was controlled by
the degradation of the hydrogelmatrix rather than its swelling
behavior.
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4. Conclusion
This study described the development and evaluation of novel
natural polymers-based nano-microparticulate system to
improve the dissolution of curcumin under gastrointestinal
conditions. The encapsulation of curcumin into chitosan
nanoparticles showed significant enhancement of curcumin
dissolution in aqueous media. A high percentage (over 95%)
of the loaded curcumin was released after 7 h incubation in a
pH 7.4 buffer solution upon using freeze-driedmicroparticles
with alginate/carrageenan ratio of 50 : 50. It was found that
carrageenan plays an important role in improving the release
pattern of curcumin from the developed hydrogel matrices
as higher release was observed in formulations with higher
content of carrageenan. The study also demonstrated that
some of the developed nano-microparticulate formulations
(such as FD3) are very promising and need to be further
investigated in vivo.
In conclusion, by taking advantage of the characteristics
of natural polymers such as chitosan, alginate, and car-
rageenan, the drug release can be modulated by taking into
consideration the ability of the polymers to form strong or
weak hydrogel networks.
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